Gyre Therapeutics reported Q2 2024 revenues of $25.2M, down from $29.3M in Q2 2023, with net income of $4.5M. The company maintained a strong financial position with $16.1M in cash and equivalents as of June 30, 2024.Key developments include NMPA approval of avatrombopag for CLD-associated thrombocytopenia and acquisition of nintedanib rights for IPF treatment. The company also received IND approval from NMPA for F230 in pulmonary arterial hypertension, with Phase 1 trial expected to begin in 2025.For F351, Gyre expects topline data from the Phase 3 trial in CHB-associated liver fibrosis by early 2025 and plans to submit U.S. IND for MASH-associated liver fibrosis by late 2024. The company's commercial product ETUARY generated $25.1M in sales for Q2 2024, with expanded product offerings expected to support future revenue growth.

Gyre Therapeutics reported Q2 2024 revenues of $25.2M, down from $29.3M in Q2 2023, with net income of $4.5M. The company maintained a strong financial position with $16.1M in cash and equivalents as of June 30, 2024.Key developments include NMPA approval of avatrombopag for CLD-associated thrombocytopenia and acquisition of nintedanib rights for IPF treatment. The company also received IND approval from NMPA for F230 in pulmonary arterial hypertension, with Phase 1 trial expected to begin in 2025.For F351, Gyre expects topline data from the Phase 3 trial in CHB-associated liver fibrosis by early 2025 and plans to submit U.S. IND for MASH-associated liver fibrosis by late 2024. The company's commercial product ETUARY generated $25.1M in sales for Q2 2024, with expanded product offerings expected to support future revenue growth.